arrow
S

Shahzad Raza

cleveland clinic lerner college of medicine
H指数:27
被引数:2,894

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early treatment failure after ciltacabtagene autoleucel in multiple myeloma with high-risk features: implications for risk-informed care

具有高危特征的多发性骨髓瘤在应用cilta-cabtagene autoleucel治疗后早期失败:对风险知情护理的启示

2026-10-220
OAAI
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
2026-07-270
OA
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

elranatamab治疗多发性骨髓瘤的真实世界结局: 来自美国多发性骨髓瘤免疫治疗联盟的多中心分析

2026-03-270
OAAI
Diagnostic Accuracy of Fat Pad Sampling and Bone Marrow Biopsy for AL Amyloidosis: A Systematic Review and Meta-Analysis

AL淀粉样变性脂肪垫取样和骨髓活检的诊断准确性:系统评价和Meta分析

2026-01-010
OA
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab

用Talquetamab和Teclistamab双重靶向髓外骨髓瘤

2025-12-012
PRE
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

外周髓外和骨旁浆细胞瘤对使用teclistamab治疗的多发性骨髓瘤患者治疗结局的影响:美国骨髓瘤免疫治疗联盟真实世界经验

2025-11-280
OAAI
The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis

系统性AL淀粉样变性中双特异性T细胞衔接疗法的安全性与有效性

2025-11-010
PRE
Current management of non-amyloidosis monoclonal gammopathy of renal significance: Clinical features, treatment selections, responses and renal outcomes

非淀粉样变性肾损害意义单克隆丙种球蛋白病的当前管理:临床特征、治疗选择、疗效及肾脏结局

2025-10-230
OAAI
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists

复发难治性多发性骨髓瘤的管理:面向社区肿瘤科医师的循证指南

2025-09-270
PRE
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium

氟达拉滨淋巴细胞清除暴露与伊达比特-维克鲁塞尔治疗后复发性/难治性多发性骨髓瘤的毒性相关:来自美国骨髓瘤免疫治疗联盟的真实世界经验

2025-09-170
PREAI
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Dhakal, B.; Akhtar, O.S.; Fandrei, D.; Jensen, A.; Banerjee, R.; Pan, D.; Richard, S.; Friend, R.; Rees, M.J.; Costello, P.; 等. 多发性骨髓瘤的序贯靶向治疗:Talquetamab,一种GPRC5D双特异性抗体,作为BCMA CAR-T细胞疗法的桥梁。Blood 2025. [Google Scholar] [CrossRef]

Blood
IF23.1
2025-08-050
PRE